This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Migraine: Mining the Outer Reaches of Headache Science

Migraine: Mining the Outer Reaches of Headache Science


Slide Lecture Series

Time to Complete

1.50 hours


October 1, 2019


October 1, 2020
Add to Queue

Maximum Credits

0.50 per module for a total possible of 1.50 AMA PRA Category 1 CreditsTM

Accredited Provider

This activity is provided by Forefront Collaborative.

Commercial Supporter

This activity is supported by an educational grant from Lilly.

For further information concerning Lilly grant funding, visit

Program Description

The world of migraine treatment is undergoing dramatic advances. In this CME presentation, faculty used a HoloLens—a mixed-reality device—to demonstrate the pathophysiology and mechanisms of action (MOAs) of acute and preventive treatments. Learners will witness scenes from the cortical level, be zoomed in to neural pathways and, closer still, to the interplay between receptors, ligands, and compounds. The cause-and-effect of biological and therapeutic interactions will be explored and applied to clinical decision-making, supported by a case series and faculty discussion.

Intended Audience

The activity is designed for headache specialists and other healthcare professionals, including general neurologists, primary care physicians, physician assistants, nurse practitioners, nurses, and pharmacists who treat patients with migraine.

Educational Objectives

Upon completion of the activity, participants should be able to:

  • Describe new concepts in migraine pathophysiology and MOA of new therapeutics.
  • Analyze safety and efficacy profiles for new and emerging therapies in acute and preventive treatment of migraine.
  • Develop treatment plans in line with current standards of practice and guidelines for acute and preventive management of migraine.
  • Effectively communicate with patients using shared decision-making to diagnose and treat migraine early and accurately.
  • Integrate burden of migraine and its impact on quality of life into the treatment of patients.

Accreditor Disclosure of Conflicts of Interest Policy

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.


The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

Stephen D. Silberstein, MD
Professor of Neurology
Thomas Jefferson University
Jefferson Headache Center
Philadelphia, Pennsylvania

Dr. Silberstein receives, or has received, honoraria for consultation and/or participation on an advisory panel from Abide Therapeutics, Alder Biopharmaceuticals, Allergan, Amgen, Avanir Pharmaceuticals, Biohaven Pharmaceuticals, Cefaly, Curelator, Dr. Reddy’s, Egalet Corporation, GlaxoSmithKline Consumer Health Holdings, eNeura, electroCore, Impel NeuroPharma, Lilly, Medscape, Novartis, Satsuma Pharmaceuticals, Supernus Pharmaceuticals, Teva Pharmaceutical Industries, Theranica, and Trigemina.

Jessica Ailani, MD, FAHS
Medstar Georgetown Headache Center
Associate Professor of Neurology
Medstar Georgetown University Hospital
Washington, DC

Dr. Ailani has consulted for Allergan, Alder Biopharmaceuticals, Amgen, Lilly, ElectroCore, and Promius; she has participated in a speaker’s bureau for Allergan, Amgen, Avanir Pharmaceuticals, Lilly, electroCore, Promius, and Teva Pharmaceutical Industries; Dr. Ailani has participated in an advisory board for Biohaven, Impel, and Satsuma Pharmaceuticals; she has contracted research from Amgen.

Stewart J. Tepper, MD
Professor of Neurology
Geisel School of Medicine at Dartmouth
Dartmouth Headache Center Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire

Dr. Tepper has grants for research from Alder Biopharmaceuticals, Allergan, Amgen, ATI, Dr. Reddy’s, electroCore, eNeura, Neurolief, Scion NeuroStim, Teva Pharmaceutical Industries, and Zosano; he has consulted or participated on an advisory board for Acorda, Alder Biopharmaceuticals, Alexza, Allergan, AlphaSights, Amgen, ATI, Axsome Therapeutics, BioDelivery Sciences International, Biohaven, Cefaly, Charleston Labs, DeepBench, Dr. Reddy’s, electroCore, Lilly, eNeura, ExpertConnect, GLG, Guidepoint Global, GSK, Impel, M3 Global Research, Magellan Rx Management, Medicxi, Navigant Consulting, Neurolief, Nordic BioTech, Novartis, Pfizer, Reckner Healthcare, Relevale, Satsuma Pharmaceuticals, Scion NeuroStim, Slingshot Insights, Sorrento, Sudler & Hennessey, Supernus Pharmaceuticals, Teva Pharmaceutical Industries, Theranica, Trinity Partners, XOC, and Zosano; Dr. Tepper has stock options in ATI and has royalties in Springer; he receives salary from Dartmouth-Hitchcock Medical Center, American Headache Society.

Wade M. Cooper, DO
Headache and Neuropathic Pain Program
University of Michigan
Ann Arbor, Michigan

Dr. Cooper has consulted for and has ownership interest in Dolor Technologies; Dr. Cooper has participated in an advisory board for Promius.

Accredited Provider Disclosure

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:
Planner (Forefront Collaborative): Sydney Pate, MS

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:
Planner (Forefront Collaborative): Lily Zurkovsky, PhD, has personal stock in Teva Pharmaceutical Industries.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Forefront Collaborative designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 CreditTM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Part II Points

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To Claim this credit type, please fill out the required information in the Evaluation of the activity.

ABPN MOC Part II Points

The American Board of Psychiatry and Neurology has reviewed Migraine: Mining the Outer Reaches of Headache Science and has approved this program as part of a comprehensive program, which is mandated by the ABMS as a necessary component of maintenance of certification.

To Claim this credit type, please fill out the required information in the Evaluation of the activity.

Disclosure of Unlabeled Use

This continuing medical education activity will include reference to unlabeled or unapproved uses of drugs or devices.


The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.


To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue